Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Open accessThe DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
OverviewDNA damaging chemotherapy is the first line of treatment for certain cancers, but its longterm success is often marred by the eventual acquisition of chemoresistance.Other cancers cannot be treated because they are intrinsically resistant to such chemotherapy.These 2 types of resistance are coupled in the context of translesion synthesis (TLS), which is carried out by specialized TLS DNA polymerases that can replicate past DNA lesions but in a lower fidelity manner.First, TLS DNA polymerases permit the bypass of modified DNA bases during DNA synthesis, thereby allowing proliferation to continue in the presence of chemotherapy, an issue of particular relevance to intrinsic drug resistance.Second, mistakes introduced by TLS polymerases copying over DNA lesions introduced during the chemotherapy lead to mutations that contribute to acquired resistance.These dual functions of mutagenic TLS polymerases with respect to chemoresistance make these proteins very promising targets for adjuvant therapy.The major branch of mutagenic TLS requires REV1, a Y family DNA polymerase that recruits other TLS polymerases with its C-terminal domain (CTD) including POL z, which is also required.Recent evidence obtained using mouse models is summarized, which shows that interfering with REV1/POL z-dependent mutagenic TLS during DNA damaging chemotherapy can help overcome problems due to both intrinsic resistance and acquired resistance.Ways to develop drugs that block mutagenic TLS are also considered, including taking advantage of structural knowledge to target key protein-protein interfaces.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because TLS events may protect tumor cells by favoring DNA replication”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [108]
In the citing paper
“TLS is considered a potential target in cancer therapy [98,108,109]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krokan, H. E., & Bjoras, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012583 · Cited by 1,322
The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase η
Masutani, C., Kusumoto, R., Yamada, A., Dohmae, N., Yokoi, M., Yuasa, M., Araki, M., Iwai, S., Takio, K., & Hanaoka, F. (1999) · Nature · doi:10.1038/21447 · Cited by 1,292 · cited 3×
“Pamoic acid, aurintricarboxylic acid, and ellagic acid were found to inhibit POL ι and POL η [112], while candesartan cilexetil inhibited the enzymatic function of POL κ as well as enhanced UV-induced cytotoxicity in xeroderma pigmentosum-variant (XP-V) cells [116].”
BackgroundInfluentialNucleotide Excision Repair in Eukaryotes
Scharer, O. D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012609 · Cited by 801
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757 · cited 1×
“Many tumors, including most pancreatic adenocarcinomas, nonsmall cell lung cancers, and aggressive brain tumors, as well as most metastatic malignancies, fail to significantly regress following chemotherapy [2].”
BackgroundInfluentialY-family DNA polymerases and their role in tolerance of cellular DNA damage
Sale, J. E., Lehmann, A. R., & Woodgate, R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3289 · Cited by 665 · cited 2×
“REV1 functions as a principle scaffolding protein, which recruits other TLS polymerases to first insert a nucleotide opposite the DNA lesion and then eventually help extend the distorted primer-template terminus, in what is recognized as the two-step mechanism of TLS (Fig 2) [7, 8, 89].”
BackgroundMechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660 · cited 1×
“This can include the activation of drug efflux pumps or detoxifying processes that effectively reduce intracellular drug concentration [1].”
BackgroundEukaryotic polymerases ι and ζ act sequentially to bypass DNA lesions
Johnson, R. E., Washington, M. T., Haracska, L., Prakash, S., & Prakash, L. (2000) · Nature · doi:10.1038/35023030 · Cited by 632 · cited 2×
“POL ζ4 B-family (REV3 [REV3] polymerase, REV7 [REV7], POLD2 and POLD3 accessory subunits) [65] • POL ζ4 mediate inefficient TLS across CPDs, (6–4) photoproducts, adducted residues and AP sites, but an error free bypass of thymine glycols [53, 66, 67] • Serves as the key extender polymerase during TLS [68] • REV3 prote…”
BackgroundREV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance
Waters, L. S., Minesinger, B. K., Wiltrout, M. E., D'Souza, S., Woodruff, R. V., & Walker, G. C. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00034-08 · Cited by 591 · cited 2×
“REV1 functions as a principle scaffolding protein, which recruits other TLS polymerases to first insert a nucleotide opposite the DNA lesion and then eventually help extend the distorted primer-template terminus, in what is recognized as the two-step mechanism of TLS (Fig 2) [7, 8, 89].”
BackgroundSelf-citationDeoxycytidyl transferase activity of yeast REV1 protein
Nelson, J. R., Lawrence, C. W., & Hinkle, D. C. (1996) · Nature · doi:10.1038/382729a0 · Cited by 572 · cited 1×
“REV1 (REV1) Y-family • Exclusively inserts dCMPs opposite template Gs, abasic sites, and adducted G residues [13, 14] • Acts as a scaffolding protein by interacting with both POL ζ and RIR containing POL η, POL κ and POL ι [15, 16] • Generates G/C substitutions during Ig gene somatic hypermutation [17] • Accumulates i…”
Background
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
“DNA lesions, single strand breaks (SSB) and double strand breaks (DSB), are repaired by different DDR pathways including BER, NER, mismatch repair (MMR), homologous recombination (HR), non-homologous end joining (NHEJ), translesion synthesis (TLS) and Fanconi anemia (FA) pathway (Bellon et al., 1991; Tian et al., 2015…”
BackgroundDNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy
Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194
Self-citationTaglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J.-W., Wu-Baer, F., Baer, R., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 173
Metadata
- Authors
- Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C.
- Affiliations
- Massachusetts Institute of Technology (US)
- Corresponding author
- Walker, Graham C.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-17
- Volume
- 13
- Issue
- 8
- Pages
- e1006842
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC5560539
- OpenAlex
- W2747521922
- Cited by
- 87
- References
- 120
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 5 · 2017: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PLoS eBooks
- Funders
- National Institute of Environmental Health Sciences (ES-002109, ES-015818, P30ES002109, R56ES015818, R01ES015818)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- translesion synthesis, chemoresistance, acquired drug resistance, intrinsic drug resistance, Rev1, Y-family DNA polymerases, DNA damage, chemotherapy, adjuvant therapy, protein-protein interfaces
- MeSH terms
- Animals, Antineoplastic Agents, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, DNA Replication, Humans, Drug Resistance, Neoplasm, Nucleic Acid Synthesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? https://app.cochat.ai/papers/10.1371/journal.pgen.1006842
- The paper
- Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017). Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? PLOS Genetics. https://doi.org/10.1371/journal.pgen.1006842
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.